美股A股
StockGist

InterCure Ltd.

INCRNASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Is…
$3.47+5.31%
报价 2026-11-06
市值
$41.1M
EV
–
PE (TTM)
–
预期 PE
–
52 周区间距高点 -52.1%
$3.30$7.25

筛选结果

pipeline · 2026-11-06
Filter✗ 高增长✗ Cheap✗ GARP
market cap below $300M floor

研究结论

还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。

去生成基本面报告 →

历史股价

加载中…

事件

0 条 · 随区间与图例筛选

该区间内无事件。

同行对比

同行业市值相近 · Drug Manufacturers - Specialty & Generic
公司市值今日预期营收增速毛利率PEEV/EBITDAP/FCF池
INCRInterCure Ltd.$41.1M+5.3%–0.3%––14.1x
ZYBTZhengye Biotechnology Holding Limited$71.1M+8.7%–8.3%––14.0x
TLPHTalphera, Inc.$54.5M+4.0%+29430.6%-4,075%–––
RMTIRockwell Medical, Inc.$31.2M+1.7%+4.3%17.7%––21.2x
COSMCosmos Health Inc.$30.7M+5.2%+60.2%10.3%–––
IXHLIncannex Healthcare Limited$26.8M-1.3%–-192.7%–––
SHPHShuttle Pharmaceuticals Holdings, Inc.$26.6M+10.8%–0%–––
CPHIChina Pharma Holdings, Inc.$24.5M+7.5%–-9.3%–––
SCYXSCYNEXIS, Inc.$22M+6.1%-87.9%100%–––
同行中位数––+32.3%4.2%––17.6x

研究全文

L2 基本面 memo

尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。

财务报表

报告货币 ILS(非美元)
Metric
2025-12-31
Q4 2025
2025-09-30
Q3 2025
2025-06-30
Q2 2025
2025-03-31
Q1 2025
2024-12-31
Q4 2024
2024-09-30
Q3 2024
2024-06-30
Q2 2024
2024-03-31
Q1 2024
RevenueILS 70.1MILS 70.1MILS 65MILS 65MILS 56.6MILS 56.6MILS 62.9MILS 62.9M
Gross Margin0.3%0.3%30.9%30.9%0.3%0.3%33.1%33.1%
Operating Margin-23.5%-23.5%4.4%4.4%-68.7%-68.7%8.4%8.4%
Net IncomeILS -17MILS -17MILS -852,000ILS -852,000ILS -34.6MILS -34.6MILS 716,500ILS 716,500
Diluted EPS-1.7-1.7-0.08-0.08-3.95-3.950.080.08
Operating Cash FlowILS 16.8MILS 2.3MILS 6.1MILS 6.1MILS 0ILS 0ILS -21.7MILS -21.7M

研究材料